Synergetics v. Alcon Laboratories
This article was originally published in The Gray Sheet
Alcon will pay Synergetics $32 million for the right to sell certain Synergetics products on a co-exclusive basis under a licensing deal that also settles all pending litigation between the firms, announced April 27. Other terms were not disclosed. Synergetics had sued Alcon in 2008, accusing Alcon of anti-competitive behavior and alleging that Alcon used its "monopoly power" in the vitrectomy device market to boost sales of surgical illumination devices and related accessories, according to Synergetics' annual report. Alcon then countersued, alleging patent infringement and unfair competition
You may also be interested in...
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.